CAL-27 Xenograft Model Service for Head and Neck Cancer

The CAL-27 cell line, established from a human squamous cell carcinoma of the tongue, serves as a highly representative and clinically relevant in vivo platform for investigating the pathogenesis of oral cavity squamous cell carcinomas and evaluating the therapeutic efficacy of novel oncology interventions. As a specialized pre-clinical contract research organization, Alfa Cytology delivers a comprehensive, turn-key CAL-27 Xenograft Model Service that combines scientific rigor with optimized experimental workflows to accelerate your head and neck cancer drug discovery programs.

Overview of CAL-27 Xenograft Model for Head and Neck Cancer

The CAL-27 xenograft model is an indispensable in vivo translational tool widely utilized in head and neck squamous cell carcinoma (HNSCC) research, specifically for tumors originating in the oral cavity. Developed by inoculating human CAL-27 tongue squamous cell carcinoma cells into highly immunodeficient or immunocompromised mice, this model effectively recapitulates the histological architecture, hyperkeratinized patterns, and aggressive local growth characteristics observed in human clinical presentations.

Biologically, the CAL-27 model exhibits rapid and predictable growth kinetics, ensuring excellent reproducibility across large experimental cohorts over extended therapeutic windows. Characterized by specific molecular alterations common to oral cancers, including the overexpression of epidermal growth factor receptor (EGFR) and p53 mutations, it provides an ideal physiological microenvironment for targeted mechanistic studies. Consequently, the model is globally utilized to assess the therapeutic potency of small molecule kinase inhibitors, monoclonal antibodies, cytotoxic agents, and combinatorial radiotherapeutic strategies designed to overcome treatment resistance in head and neck malignancies.

Fig 1. Orthotopic tongue cancer developed by submucosal injection with CAL-27 cells. (Sahasakul Y, et al., 2022)

Cell Line Information: CAL-27

The CAL-27 cell line was derived in 1982 from a 56-year-old Caucasian male patient suffering from a poorly differentiated squamous cell carcinoma of the tongue. These cells present an adherent, polygonal, epithelial-like morphology under standard in vitro cultivation and possess well-documented genetic profiles that align closely with standard clinical profiles of oral cavity cancers.

Partnering with Alfa Cytology ensures that your oral cancer pre-clinical studies benefit from exceptional technical precision and highly reproducible experimental datasets. Our specialized scientific team carefully monitors every phase of the project---ranging from rigorous baseline cell preparation to high-resolution physiological validation---empowering global pharmaceutical and biotechnology researchers to confidently advance their therapeutic candidates toward clinical evaluation.

Our Services

Workflow of CAL-27 Xenograft Model Construction

• Cell Culture & Quality Control: Human CAL-27 cells are cultured in vitro using certified nutrient growth media under optimized and strictly monitored environmental parameters. Comprehensive quality control profiling, consisting of mandatory Short Tandem Repeat (STR) authentication and mycoplasma clearance verification, is conducted prior to harvesting to guarantee phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunocompromised mice (such as BALB/c Nude or NOD/SCID strains) are carefully selected based on the specific requirements of the study layout. The animals are housed within controlled facility parameters for a designated period to establish stable physiological baselines and ensure general health compliance.
• Precision Inoculation: A calibrated suspension of high-viability CAL-27 cells is prepared and blended with a validated biological matrix carrier to promote spatial cell distribution and optimize the initial engraftment process. The cellular mixture is precisely injected in vivo into the target cohorts via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following the establishment of palpable or measurable tumors, growth kinetics are systematically monitored and recorded using high-precision digital calipers. Animal body weights, physiological statuses, and general welfare behavior are routinely cataloged to establish a dependable and comprehensive growth kinetic profile.
• Stratification & Dosing: Once the expanding tumor volumes reach a predetermined, statistically optimal range, animals are randomized into specific therapeutic cohorts. This stratification step perfectly balances baseline tumor parameters across all groups prior to initiating custom dosing and efficacy evaluation protocols.

Fig 2. CAL-27 Xenograft Model Construction Workflow

Case Study - CAL-27 Xenograft Model Development

In a recent pre-clinical efficacy validation program, a CAL-27 xenograft model was constructed to evaluate a novel small-molecule inhibitor targeting the EGFR signaling pathway. Following precision subcutaneous inoculation of human CAL-27 cells into BALB/c Nude mice, the tumors achieved a uniform engraftment rate of over 95% and demonstrated consistent, robust growth kinetics throughout the 28-day study timeline. Stratified animals subjected to therapeutic dosing showed a significant, dose-dependent reduction in tumor volume compared to control groups, validating the model's high sensitivity, strong predictive value, and statistical reliability for screening head and neck cancer therapeutics.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of diverse squamous cell carcinoma lineages, ensuring dependable in vivo translational modeling.
• Rigorous Quality Standards: Meticulous cell validation and stringently managed workflows that eliminate confounding biological variables across every stage of development.
• Tailored Experimental Design: Highly flexible parameters that accommodate diverse mouse strain selections, specialized dosing regimens, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every study finishes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validation.

Contact us

Accelerating your head and neck squamous cell carcinoma pipeline demands a pre-clinical partner capable of executing rigorous, high-precision in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing utilizing the CAL-27 platform, please reach out to us today. The oncology team at Alfa Cytology is fully prepared to assist you with protocol design, provide customized operational insights, and deliver the reliable data necessary to advance your pipeline.

For research use only. Not intended for any clinical use.